NVG-2089 Clinical Trials

2 recruitingDrug

Phase 22

Status

RecruitingNot yet recruitingEnrolling by invitationActive, not recruiting

Sex

MaleFemale

Your Age

Shows trials you qualify for by age

Phase

Phase 1Phase 2Phase 3Phase 4Early Phase 1Not Applicable

Study Type

InterventionalObservational

Country

United StatesCanadaUnited KingdomAustraliaGermanyFranceSpainItaly

Showing 1–2 of 2 trials

Recruiting

Phase 2

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)

Nuvig Therapeutics, Inc.30 enrolled1 locationNCT07095127

Recruiting

Phase 2

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Chronic Inflammatory Demyelinating Polyneuropathy

Nuvig Therapeutics, Inc.60 enrolled1 locationNCT07027111

ClinicalTrialsFinder

Helping patients and researchers find recruiting clinical trials. Updated regularly from ClinicalTrials.gov and ANZCTR.

Browse

Browse Conditions
Browse Drugs
Browse Locations
Browse Institutions
Search Trials
Get Trial Alerts

Resources

Clinical Trial Guides
FAQ
About Us
Contact
Partnerships
ClinicalTrials.gov
ANZCTR

Data Source

Trial data sourced from ClinicalTrials.gov and ANZCTR (Australian New Zealand Clinical Trials Registry)

Updated regularly to reflect the latest trial information

Medical Disclaimer: This site is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making decisions about participating in a clinical trial. Trial information may change; verify details directly with the trial sponsor or at the relevant registry (ClinicalTrials.gov or ANZCTR).

|

Privacy Policy Terms of Service

Data provided by ClinicalTrials.gov & ANZCTR